Article
Oncology
Stefano Cascinu, Gyorgy Bodoky, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, Gunnar Folprecht, Sumitra Ananda, Gustavo Girotto, Zev A. Wainberg, Maria Luisa Limon Miron, Jaffer Ajani, Ran Wei, Astra M. Liepa, Roberto Carlesi, Michael Emig, Atsushi Ohtsu
Summary: In the RAINBOW study, ramucirumab plus paclitaxel showed higher objective response rate than the control arm in previously treated advanced gastric or gastroesophageal junction adenocarcinoma patients, with longer response duration, leading to improved quality of life.
Article
Oncology
Sylvie Lorenzen, Peter Thuss-Patience, Claudia Pauligk, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Michael Stahl, Peter Reichardt, Martin Soekler, Daniel Pink, Stefan Probst, Axel Hinke, Thorsten O. Goetze, Salah E. Al-Batran
Summary: This study reported the efficacy and safety analyses of FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab in patients with metastatic gastroesophageal adenocarcinoma. Although overall survival rates were similar between the two groups, FOLFIRI plus ramucirumab showed better objective response rates and progression-free survival.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Sena Valcarcel, Javier Gallego, Paula Jimenez-Fonseca, Marc Diez, Eva Martinez de Castro, Raquel Hernandez, Virginia Arrazubi, Ana Custodio, Juana Maria Cano, Ana Fernandez Montes, Ismael Macias, Laura Visa, Aitana Calvo, Rosario Vidal Tocino, Nieves Martinez Lago, Maria Luisa Limon, Monica Granja, Mireia Gil, Paola Pimentel, Lola Macia-Rivas, Carolina Hernandez Perez, Montserrat Mangas, Alfonso Martin Carnicero, Paula Cerda, Lucia Gomez Gonzalez, Francisco Garcia Navalon, Ma Dolores Mediano Rambla, Marta Martin Richard, Alberto Carmona-Bayonas
Summary: This study compared the use of ramucirumab-paclitaxel and chemotherapy in second-line advanced gastroesophageal cancer based on HER2 status, and analyzed prognostic factors. The results showed that regardless of HER2 status, ramucirumab-paclitaxel treatment was superior to chemotherapy in terms of PFS, OS, and response rate.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Genetics & Heredity
Seung Tae Kim, Jason K. Sa, Sung Yong Oh, Kyung Kim, Jung Yong Hong, Won Ki Kang, Kyoung-Mee Kim, Jeeyun Lee
Summary: The study identified a subset of GC patients with distinct clinical response to ramucirumab therapy through prospective molecular characterization. The results demonstrate the feasibility of personalized therapeutic opportunities in gastric cancer.
Article
Oncology
Takako Eguchi Nakajima, Shigenori Kadowaki, Keiko Minashi, Tomohiro Nishina, Takeharu Yamanaka, Yuichiro Hayashi, Naoki Izawa, Kei Muro, Shuichi Hironaka, Takeshi Kajiwara, Yutaka Kawakami
Summary: The study aimed to investigate the safety and efficacy of nivolumab with paclitaxel plus ramucirumab in advanced gastric cancer, showing promising antitumor activity with manageable toxicities, suggesting the need for further research to determine optimal treatment strategies.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Sylvie Lorenzen, Alix Schwarz, Claudia Pauligk, Eray Goekkurt, Gertraud Stocker, Jorge Riera Knorrenschild, Gerald Illerhaus, Tobias Dechow, Markus Moehler, Jean-Charles Moulin, Daniel Pink, Michael Stahl, Marina Schaaf, Thorsten Oliver Goetze, Salah-Eddin Al-Batran
Summary: The RAMIRIS III trial evaluates the efficacy of FOLFIRI-Ram regimen in taxane-pretreated patients with advanced GEA. The completed RAMIRIS II trial demonstrated the feasibility and efficacy of FOLFIRI-Ram, especially in patients pre-treated with docetaxel. If the RAMIRIS III trial confirms these results, it will have implications for the current treatment guidelines.
Article
Oncology
Menglong Zhou, Wang Yang, Yan Xuan, Wei Zou, Yaqi Wang, Zhiyuan Zhang, Jing Zhang, Miao Mo, Changming Zhou, Yuan Liu, Wenming Zhang, Zhaozhen Zhang, Yiping He, Weiwei Weng, Cong Tan, Lei Wang, Dan Huang, Weiqi Sheng, Huanhuan Li, Hui Zhu, Yan Wang, Lijun Shen, Hui Zhang, Juefeng Wan, Guichao Li, Hua Huang, Yanong Wang, Zhen Zhang, Xiaowen Liu, Fan Xia
Summary: This article presents a randomized phase II study on the perioperative treatment of locally advanced gastric cancer (LAGC), exploring the efficacy and safety of perioperative chemotherapy, PD-1 antibody, and preoperative chemoradiation. The study aims to compare the treatment protocols and evaluate their impact on outcomes.
Article
Oncology
Tomoyuki Kakuta, Hiroshi Yabusaki, Takeo Bamba, Masaki Aizawa, Hitoshi Nogami, Tatsuya Nomura, Atsushi Matsuki, Satoshi Maruyama, Yasumasa Takii, Satoru Nakagawa
Summary: This study assessed the clinical outcomes of RAM plus PTX therapy in advanced gastric cancer patients, finding that the treatment is effective even in patients who have previously received DOC-containing chemotherapy, especially if the interval is > 6 months.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Bum Jun Kim, Hee-Jung Jee, Sun Young Rha, Hye Sook Han, Min-Hee Ryu, Se Hoon Park, Jong Gwang Kim, Woo Kyun Bae, Keun-Wook Lee, Do-Youn Oh, Ji-Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young Zang
Summary: In patients with HER2-positive gastric or gastro-esophageal junction adenocarcinoma, second-line treatment with ramucirumab plus paclitaxel showed a significantly higher objective response rate compared to patients with HER2-negative disease. However, the increased response to treatment did not correlate with an improvement in overall survival (OS).
Article
Medicine, Research & Experimental
Tsutomu Namikawa, Akira Marui, Keiichiro Yokota, Yuki Fujieda, Masaya Munekage, Sunao Uemura, Hiromichi Maeda, Hiroyuki Kitagawa, Michiya Kobayashi, Kazuhiro Hanazaki
Summary: The case presentation highlights the successful conversion surgery of a gastric cancer patient who responded well to second-line treatment with ramucirumab plus paclitaxel. This approach resulted in the complete disappearance of liver metastases and allowed for total gastrectomy with D2 lymphadenectomy. Despite recurrence and subsequent treatments, further evaluation and studies are necessary to establish the effectiveness of this treatment strategy in selected patients with unresectable advanced gastric cancer.
Article
Oncology
Omar Abdel-Rahman, Karen Mulder, Jacob Easaw
Summary: The study revealed that the combination of ramucirumab and paclitaxel in metastatic gastric/lower esophageal adenocarcinoma patients after first-line treatment is associated with improved overall survival. Younger age and lower Charlson Comorbidity Index were factors related to the use of palliative chemotherapy. Urban dwellers in Calgary or Edmonton zones had better overall survival outcomes compared to those living in rural areas.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2021)
Article
Gastroenterology & Hepatology
Rui-Hua Xu, Yanqiao Zhang, Hongming Pan, Jifeng Feng, Tao Zhang, Tianshu Liu, Yanru Qin, Shukui Qin, Xianli Yin, Baorui Liu, Yi Ba, Nong Yang, Pei Jye Voon, Suebpong Tanasanvimon, Chan Zhou, Wan Li Zhang, Lin Shen
Summary: The RAINBOW-Asia study conducted in China and other Asian countries showed that the combination of ramucirumab and paclitaxel is effective and safe for patients with advanced gastric or GEJ adenocarcinoma in the Asian population, predominantly Chinese, as a second-line treatment option.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Oncology
Hye Sook Han, Bum Jun Kim, Hee-Jung Jee, Min-Hee Ryu, Se Hoon Park, Sun Young Rha, Jong Gwang Kim, Woo Kyun Bae, Keun-Wook Lee, Do-Youn Oh, In-Ho Kim, Sun Jin Sym, So Yeon Oh, Hyeong Su Kim, Ji-Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young Zang
Summary: This study analyzed real-world data of patients with gastric or GEJ cancer treated with ramucirumab plus paclitaxel in South Korea, showing an objective response rate of 15.1% and disease control rate of 57.7% in second-line treatment. The study also identified factors negatively associated with overall survival and demonstrated the efficacy and safety of this treatment option.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Oncology
Dae-Ho Choi, Jeeyun Lee, Ho Yeong Lim, Won Ki Kang, Jae Yeon Jang, Youngkyung Jeon, Sun Young Jeong, Ye Ji Jung, Seung Tae Kim
Summary: This study investigated the efficacy of combining ramucirumab and paclitaxel in advanced gastric cancer patients based on PD-L1 expression. The analysis suggested that a PD-L1 CPS cutoff of 10 might be a novel biomarker for predicting survival in AGC patients treated with this combination therapy.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2023)
Article
Chemistry, Medicinal
M. Kimura, E. Usami, H. Teramachi, T. Yoshimura
Summary: This study found that grade ≥1 neutropenia and the number of anti-cancer drugs used were independently associated with survival in patients receiving paclitaxel plus ramucirumab as second line chemotherapy for advanced gastric cancer. Patients with grade ≥1 neutropenia had significantly prolonged treatment durations compared to those without, indicating potential benefits of this therapy for patients with initial neutropenia.